Today, Voluntis launched the Insulia Savings Program, which gives Insulia users the opportunity to benefit from a $0 copay for up to twelve months. Once the provider prescribes Insulia and patients begin using it, they can then apply for the program online at insulia.com/savings.
Insulia® is a prescription-only digital companion for people and their care teams using basal insulin to treat type 2 diabetes. It provides automated basal insulin dose recommendations and coaching messages for people with type 2 diabetes while enabling the health care team to remotely monitor progress.
“We want to make sure that Insulia can be adopted by anyone who needs help with their dose titration,” said Pierre Leurent, CEO of Voluntis. “And we recognize that cost can be an issue for many. We hope that by offering Insulia at a $0 copay, we can relieve that burden and allow them to focus on their treatment.”
Once the patient has signed up for the program, a credit will be applied to cover all out-of-pocket costs with the balance submitted to the patient’s health insurance plan for coverage. The program is intended for patients with commercial health insurance that have a valid prescription from their healthcare provider for Insulia. If a patient has primary health insurance coverage through a Federal or State program, the patient is still encouraged to apply as other programs or options may be available (subject to applicable laws and restrictions). Additional detail is available by visiting the Insulia Savings Program website.
Insulia® provides automated basal insulin dose recommendations and coaching messages for people with type 2 diabetes while enabling the health care team to remotely monitor progress. A healthcare practitioner prescribes Insulia using their dedicated web portal and sets up the treatment plan rules that will adjust basal insulin dosing based on the person’s specific needs. The user then receives an activation code to get started with their personalized app. Once downloaded, the app uses blood glucose readings and any hypo symptoms to recommend doses in real-time. These are constantly updated using clinical algorithms built into the application. Data is automatically shared with the health care team, who can remotely monitor the patient’s progress toward their goal thanks to tailored notifications. This enables providers to deliver tailored telemedicine services, a practice increasingly supported by payers worldwide. Insulia is available for people using any brand of basal insulin including Lantus®, Levemir®, Toujeo®, Tresiba® (U-100) and Basaglar®. For more information, visit www.insulia.com.
Voluntis creates digital companions that empower people to self-manage their treatment in remote collaboration with their health care teams. Dedicated to chronic conditions, Voluntis’ products aim to personalize treatment, support team-care coordination and improve real-world outcomes. Voluntis leverages its expertise in digitizing clinical algorithms and its technology platform to design its companion solutions. These include Insulia and Diabeo in diabetes as well as eCO and Zemy in oncology. Voluntis has long-standing partnerships with leading life science companies such as Sanofi, Roche and AstraZeneca. It is a founding member of the Digital Therapeutics Alliance. For more information, visit http://www.voluntis.com/.